The brain shrinkage observed in Alzheimer’s may be prevented by semaglutide, the drug in Ozempic
ZEPHYR/Science Photo Library/Alamy
Ozempic and Wegovy are already transforming how we treat type 2 diabetes and obesity, and from next year another condition affecting millions of people worldwide might be added to the list: Alzheimer’s disease.
Two clinical trials investigating semaglutide, the drug in Ozempic and Wegovy, as a therapy for early Alzheimer’s are expected to conclude in 2025. If the results are positive, it could mark a breakthrough in treating this intractable condition.
Source link : https://www.newscientist.com/article/mg26435232-400-well-learn-about-ozempics-potential-for-alzheimers-disease-in-2025/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=health
Author :
Publish date : 2024-12-23 18:00:00
Copyright for syndicated content belongs to the linked Source.
